There are 594 resources available
12P - Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial
Presenter: Caicun Zhou
Session: Poster Display session
13P - Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial
Presenter: Enriqueta Felip
Session: Poster Display session
14P - Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase II trial
Presenter: ZHENGFEI ZHU
Session: Poster Display session
15P - Updated OS and final QoL and safety results of a randomised, open-label, phase III study comparing nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced NSCLC aged =70 years or with an ECOG PS of 2 (
Presenter: Herve Lena
Session: Poster Display session
16P - Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1
Presenter: Marina Garassino
Session: Poster Display session
17P - Final analysis of PERLA, a global, randomized, phase II double-blind trial of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic nonsquamous non-small cell lung cancer
Presenter: Sun Min Lim
Session: Poster Display session
18P - Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial
Presenter: Nicolas Girard
Session: Poster Display session
19P - Subgroup analysis of first-line camrelizumab plus chemotherapy in brain metastases of NSCLC: Results from the CTONG 2003 trial
Presenter: Yang-Si Li
Session: Poster Display session
20P - Cancer registry-based real-world evidence confirms efficacy of treatments comparable to KEYNOTE-189/-407 and Impower-133
Presenter: Irina Surovtsova
Session: Poster Display session
21P - Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDC*lung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study
Presenter: Johan Vansteenkiste
Session: Poster Display session